TNF-α inhibitors and rheumatoid arthritis

被引：17

作者：

Shire, MG ^{[1
]}

Muller, GW ^{[1
]}

机构：

[1] Celgene Corp, Warren, NJ 07059 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 05期

关键词：

anti-inflammatory matrix metalloproteinase; MMP; PDE; phosphodiesterase; rheumatoid arthritis; rolipram; thalidomide; TNF converting enzyme; TACE; TNF-alpha; tumour necrosis factor alpha;

D O I：

10.1517/13543776.8.5.531

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Rheumatoid arthritis (RA) is a common autoimmune disease with inflammatory manifestations in the peripheral joints. The lack of an effective and safe treatment for RA. is a major problem in modem medicine. The proinflammatory cytokine tumour necrosis factor alpha (TNF-alpha) is known to play an important role in the pathogenesis of RA and the use of anti-TNF-alpha. agents as a strategy for the treatment of inflammatory and autoimmune diseases, including RA, has become a competitive area. This review will cover the use of phosphodiesterase 4 inhibitors, matrix metalloproteinase (MMP) inhibitors and some small molecule inhibitors of TNF-alpha and their potential use in RA.

引用

页码：531 / 544

页数：14

共 48 条

[1]

ANAYA JM, 1995, J RHEUMATOL, V22, P595

[2] SELECTIVE TYPE-IV PHOSPHODIESTERASE INHIBITORS AS ANTIASTHMATIC AGENTS - THE SYNTHESES AND BIOLOGICAL-ACTIVITIES OF 3-(CYCLOPENTYLOXY)-4-METHOXYBENZAMIDES AND ANALOGS [J].

ASHTON, MJ ;

COOK, DC ;

FENTON, G ;

KARLSSON, JA ;

PALFREYMAN, MN ;

RAEBURN, D ;

RATCLIFFE, AJ ;

SOUNESS, JE ;

THURAIRATNAM, S ;

VICKER, N .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (11) :1696-1703

[3] A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders [J].

Baxter, AD ;

Bird, J ;

Bhogal, R ;

Massil, T ;

Minton, KJ ;

Montana, J ;

Owen, DA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (07) :897-902

[4] Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety [J].

Baxter, AD ;

Bhogal, R ;

Bird, JB ;

Buckley, GM ;

Gregory, DS ;

Hedger, PC ;

Manallack, DT ;

Massil, T ;

Minton, KJ ;

Montana, JG ;

Neidle, S ;

Owen, DA ;

Watson, RJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (21) :2765-2770

[5] PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].

BEAVO, JA ;

REIFSNYDER, DH .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155

[6] MATRIX METALLOPROTEINASES - A REVIEW [J].

BIRKEDALHANSEN, H ;

MOORE, WGI ;

BODDEN, MK ;

WINDSOR, LJ ;

BIRKEDALHANSEN, B ;

DECARLO, A ;

ENGLER, JA .

CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250

[7] A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].

Black, RA ;

Rauch, CT ;

Kozlosky, CJ ;

Peschon, JJ ;

Slack, JL ;

Wolfson, MF ;

Castner, BJ ;

Stocking, KL ;

Reddy, P ;

Srinivasan, S ;

Nelson, N ;

Boiani, N ;

Schooley, KA ;

Gerhart, M ;

Davis, R ;

Fitzner, JN ;

Johnson, RS ;

Paxton, RJ ;

March, CJ ;

Cerretti, DP .

NATURE, 1997, 385 (6618) :729-733

[8] The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines [J].

Bondeson, J .

GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 29 (02) :127-150

[9]

CAVALLA D, 1995, CURR MED CHEM, V2, P561

[10]

CHIKANZA IC, 1996, EXP OPIN INVEST DRUG, V5, P819

← 1 2 3 4 5 →